Applying Evolving Targeted Therapy in Acute Myeloid Leukemia

To participate in this activity, please:

Log in Sign Up

Acute Myeloid Leukemia (AML) is a biologically heterogeneous hematologic malignant neoplasm with a 5-year survival rate of 30%. Hematologist, Brian Jonas, MD, PhD, UC Davis Comprehensive Cancer, discusses standard induction, consolidation, and maintenance therapy, as well as factors to consider in individualizing intensive therapy in fit and unfit patients. Dr. Jonas presents safety and efficacy data for approved and emerging therapies that target BCL-2, FLT-3 ITD/TDK, CD33, CD47, IDH1/2, E-selectin, and SMO. Dr. Jonas utilizes case studies to share his insights in the treatment of patients with AML.

Course Credit:

0.75 ACPE Contact Hours
0.75 AMA PRA Category 1 CreditsTM
0.75 ANCC Contact Hours
0.75 CA-BRN Contact Hours
0.5 Pharmacology Hours

Dates:

Opens: 2023-09-30
Closes: 2024-09-30

Target Audience:

National audience of hematologist-oncologists, hematology advanced practitioners, hematology nurses, pathologists, emergency medicine physicians, pediatricians, primary care physicians, pharmacists, and other clinicians who diagnose or treat patients with AML.

This education activity is supported by an educational grant from AbbVie.

Accreditation Information

Accreditation

In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 0.75 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 contact hours, including 0.5 pharmacology hours.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 0.75 contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Amber Lambert, MSN, FNP-C, DNP (Nurse Planner)
No significant relationships to disclose.

Kimberly Tyler, ANP-C, AOCNP (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Brian Jonas, MD, PhD

    Professor of Medicine
    University of California, Davis
    Davis, California

Learning Objectives

  • Describe current and emerging molecular features and targets in acute myeloid leukemia (AML) that impact therapeutic decisions
  • Optimize treatment plans for patients with newly diagnosed AML, including those appropriate and inappropriate for intensive treatment
  • Discuss the most recent clinical data for emerging therapies and targets in newly diagnosed AML

Faculty Disclosures

Brian Jonas, MD, PhD

Consultant: AbbVie, BMS, Daiichi Sankyo, Genentech, Gilead, GlycoMimetics, Kymera, Rigel, Servier

Research Support: AbbVie, Amgen, AROG, Aptose, BMS, Celgene, F. Hoffmann-La Roche, Forma, Forty-Seven, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immun-Onc, Jazz, Loxo, Pfizer, Pharmacyclics, Treadwell